A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

NCT06789159 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma Refractory
Diffuse Large B Cell Lymphoma Relapsed
Epstein-Barr Virus (EBV) Infection

Interventions

DRUG: VK-2019

Sponsor

Thomas Jefferson University

Collaborators

[object Object]
[object Object]